Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form

Cardiovascular diseases such as hypertension and cardiac failure in South African children and adolescents are effectively managed long term, using a combination treatment of captopril and hydrochlorothiazide. The majority of commercially available pharmaceutical products are designed for adult pati...

Full description

Bibliographic Details
Main Authors: Mellisa T. R. Chikukwa, Roderick B. Walker, Sandile M. M. Khamanga
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/12/8/712
id doaj-32b93a69c63a4da3947cb38a711dc1ac
record_format Article
spelling doaj-32b93a69c63a4da3947cb38a711dc1ac2020-11-25T02:35:20ZengMDPI AGPharmaceutics1999-49232020-07-011271271210.3390/pharmaceutics12080712Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage FormMellisa T. R. Chikukwa0Roderick B. Walker1Sandile M. M. Khamanga2Division of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda (Grahamstown) 6140, South AfricaDivision of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda (Grahamstown) 6140, South AfricaDivision of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda (Grahamstown) 6140, South AfricaCardiovascular diseases such as hypertension and cardiac failure in South African children and adolescents are effectively managed long term, using a combination treatment of captopril and hydrochlorothiazide. The majority of commercially available pharmaceutical products are designed for adult patients and require extemporaneous manipulation, prior to administration to paediatric patients. There is a need to develop an age appropriate microparticulate dosing technology that is easy to swallow, dose and alter doses whilst overcoming the pharmacokinetic challenges of short half-life and biphasic pharmacokinetic disposition exhibited by hydrochlorothiazide and captopril. An emulsion solvent evaporation approach using different combinations of polymers was used to manufacture captopril and hydrochlorothiazide microparticles. Design of experiments was used to develop and analyse experimental data, and identifyoptimum formulation and process conditions for the preparation of the microparticles. Characterisation studies to establish encapsulation efficiency, in vitro release, shape, size and morphology of the microparticles were undertaken. The microparticles produced were in the micrometre size range, with an encapsulation efficiency >75% for both hydrochlorothiazide and captopril. The microparticulate technology is able to offer potential resolution to the half-life mediated dosing frequency of captopril as sustained release of the molecule was observed over a 12-h period. The release of hydrochlorothiazide of >80% suggests an improvement in solubility limited dissolution.https://www.mdpi.com/1999-4923/12/8/712captoprilhydrochlorothiazidemicroparticlessustained releaseemulsion solvent evaporationpaediatric
collection DOAJ
language English
format Article
sources DOAJ
author Mellisa T. R. Chikukwa
Roderick B. Walker
Sandile M. M. Khamanga
spellingShingle Mellisa T. R. Chikukwa
Roderick B. Walker
Sandile M. M. Khamanga
Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
Pharmaceutics
captopril
hydrochlorothiazide
microparticles
sustained release
emulsion solvent evaporation
paediatric
author_facet Mellisa T. R. Chikukwa
Roderick B. Walker
Sandile M. M. Khamanga
author_sort Mellisa T. R. Chikukwa
title Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
title_short Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
title_full Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
title_fullStr Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
title_full_unstemmed Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
title_sort formulation and characterisation of a combination captopril and hydrochlorothiazide microparticulate dosage form
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2020-07-01
description Cardiovascular diseases such as hypertension and cardiac failure in South African children and adolescents are effectively managed long term, using a combination treatment of captopril and hydrochlorothiazide. The majority of commercially available pharmaceutical products are designed for adult patients and require extemporaneous manipulation, prior to administration to paediatric patients. There is a need to develop an age appropriate microparticulate dosing technology that is easy to swallow, dose and alter doses whilst overcoming the pharmacokinetic challenges of short half-life and biphasic pharmacokinetic disposition exhibited by hydrochlorothiazide and captopril. An emulsion solvent evaporation approach using different combinations of polymers was used to manufacture captopril and hydrochlorothiazide microparticles. Design of experiments was used to develop and analyse experimental data, and identifyoptimum formulation and process conditions for the preparation of the microparticles. Characterisation studies to establish encapsulation efficiency, in vitro release, shape, size and morphology of the microparticles were undertaken. The microparticles produced were in the micrometre size range, with an encapsulation efficiency >75% for both hydrochlorothiazide and captopril. The microparticulate technology is able to offer potential resolution to the half-life mediated dosing frequency of captopril as sustained release of the molecule was observed over a 12-h period. The release of hydrochlorothiazide of >80% suggests an improvement in solubility limited dissolution.
topic captopril
hydrochlorothiazide
microparticles
sustained release
emulsion solvent evaporation
paediatric
url https://www.mdpi.com/1999-4923/12/8/712
work_keys_str_mv AT mellisatrchikukwa formulationandcharacterisationofacombinationcaptoprilandhydrochlorothiazidemicroparticulatedosageform
AT roderickbwalker formulationandcharacterisationofacombinationcaptoprilandhydrochlorothiazidemicroparticulatedosageform
AT sandilemmkhamanga formulationandcharacterisationofacombinationcaptoprilandhydrochlorothiazidemicroparticulatedosageform
_version_ 1724804035620372480